array(40) {
  [0]=>
  string(4) "1799"
  ["article_id"]=>
  string(4) "1799"
  [1]=>
  string(69) "Innovation in Orthopedic and Spinal Devices for Kids Still Lacking"
  ["article_title"]=>
  string(69) "Innovation in Orthopedic and Spinal Devices for Kids Still Lacking"
  [2]=>
  string(150) "Developing medical devices in general is costly, but there is funding available for companies that are willing to create products specifically for ped"
  ["short_description"]=>
  string(150) "Developing medical devices in general is costly, but there is funding available for companies that are willing to create products specifically for ped"
  [3]=>
  string(543) "
Developing medical devices in general is costly, but there is funding available for companies that are willing to create products specifically for pediatrics.
&#nl
The post Innovation in Orthopedic and Spinal Devices for Kids Still Lacking appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(543) "
Developing medical devices in general is costly, but there is funding available for companies that are willing to create products specifically for pediatrics.
&#nl
The post Innovation in Orthopedic and Spinal Devices for Kids Still Lacking appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(116) "https://www.medtechintelligence.com/news_article/innovation-in-orthopedic-and-spinal-devices-for-kids-still-lacking/"
  ["blog_url"]=>
  string(116) "https://www.medtechintelligence.com/news_article/innovation-in-orthopedic-and-spinal-devices-for-kids-still-lacking/"
  [15]=>
  string(19) "2019-03-21 19:20:25"
  ["add_date"]=>
  string(19) "2019-03-21 19:20:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-29 16:07:46"
  ["create_at"]=>
  string(19) "2019-03-29 16:07:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2131"
  ["article_id"]=>
  string(4) "2131"
  [1]=>
  string(65) "Corza Health Emerges Led by Former NuVasive, GreatCall Executives"
  ["article_title"]=>
  string(65) "Corza Health Emerges Led by Former NuVasive, GreatCall Executives"
  [2]=>
  string(150) "A Chicago-based private equity firm has tapped the former head of NuVasive and finance chief of GreatCall to start a new healthcare company in San Die"
  ["short_description"]=>
  string(150) "A Chicago-based private equity firm has tapped the former head of NuVasive and finance chief of GreatCall to start a new healthcare company in San Die"
  [3]=>
  string(324) "A Chicago-based private equity firm has tapped the former head of NuVasive and finance chief of GreatCall to start a new healthcare company in San Diego. The company, Corza Health, is headed by Greg Lucier, most recently CEO at NuVasive, and backed by the PE firm, GTCR, with money from its $5.25 billion Fund XII. […]"
  ["description"]=>
  string(324) "A Chicago-based private equity firm has tapped the former head of NuVasive and finance chief of GreatCall to start a new healthcare company in San Diego. The company, Corza Health, is headed by Greg Lucier, most recently CEO at NuVasive, and backed by the PE firm, GTCR, with money from its $5.25 billion Fund XII. […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/T99DJvLgEr8/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/T99DJvLgEr8/"
  [15]=>
  string(19) "2019-03-21 08:53:15"
  ["add_date"]=>
  string(19) "2019-03-21 08:53:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2132"
  ["article_id"]=>
  string(4) "2132"
  [1]=>
  string(73) "As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround"
  ["article_title"]=>
  string(73) "As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround"
  [2]=>
  string(150) "A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the "
  ["short_description"]=>
  string(150) "A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the "
  [3]=>
  string(362) "A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the company’s first product, Cologuard, which marked the first non-invasive, stool-based DNA screening test approved for detecting colorectal cancer. In the five years since then, Exact (NASDAQ: EXAS) […]"
  ["description"]=>
  string(362) "A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the company’s first product, Cologuard, which marked the first non-invasive, stool-based DNA screening test approved for detecting colorectal cancer. In the five years since then, Exact (NASDAQ: EXAS) […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/MIjBwJkT6fE/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/MIjBwJkT6fE/"
  [15]=>
  string(19) "2019-03-21 04:36:42"
  ["add_date"]=>
  string(19) "2019-03-21 04:36:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2011"
  ["article_id"]=>
  string(4) "2011"
  [1]=>
  string(81) "Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial"
  ["article_title"]=>
  string(81) "Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial"
  [2]=>
  string(150) "SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccine"
  ["short_description"]=>
  string(150) "SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccine"
  [3]=>
  string(248) "SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a..."
  ["description"]=>
  string(248) "SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(252) "https://www.drugs.com/clinical_trials/vaxart-announces-initiation-bivalent-norovirus-vaccine-phase-1b-clinical-trial-18101.html?utm_source=ddc&utm_medium=rss&utm_campaign=Vaxart+Announces+Initiation+of+Bivalent+Norovirus+Vaccine+Phase+1b+Clinical+Trial"
  ["blog_url"]=>
  string(252) "https://www.drugs.com/clinical_trials/vaxart-announces-initiation-bivalent-norovirus-vaccine-phase-1b-clinical-trial-18101.html?utm_source=ddc&utm_medium=rss&utm_campaign=Vaxart+Announces+Initiation+of+Bivalent+Norovirus+Vaccine+Phase+1b+Clinical+Trial"
  [15]=>
  string(19) "2019-03-20 06:03:26"
  ["add_date"]=>
  string(19) "2019-03-20 06:03:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2012"
  ["article_id"]=>
  string(4) "2012"
  [1]=>
  string(121) "Data From GARNET Study Indicates Robust Activity of Dostarlimab in Patients with Advanced or Recurrent Endometrial Cancer"
  ["article_title"]=>
  string(121) "Data From GARNET Study Indicates Robust Activity of Dostarlimab in Patients with Advanced or Recurrent Endometrial Cancer"
  [2]=>
  string(150) "London UK - 19 March 2019 -- TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentati"
  ["short_description"]=>
  string(150) "London UK - 19 March 2019 -- TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentati"
  [3]=>
  string(245) "London UK - 19 March 2019 -- TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab in women with recurrent or..."
  ["description"]=>
  string(245) "London UK - 19 March 2019 -- TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab in women with recurrent or..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/data-garnet-study-indicates-robust-activity-dostarlimab-patients-advanced-recurrent-endometrial-18091.html?utm_source=ddc&utm_medium=rss&utm_campaign=Data+From+GARNET+Study+Indicates+Robust+Activity+of+Dostarlimab+in+Patients+with+Advanced+or+Recurrent+Endometri"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/data-garnet-study-indicates-robust-activity-dostarlimab-patients-advanced-recurrent-endometrial-18091.html?utm_source=ddc&utm_medium=rss&utm_campaign=Data+From+GARNET+Study+Indicates+Robust+Activity+of+Dostarlimab+in+Patients+with+Advanced+or+Recurrent+Endometri"
  [15]=>
  string(19) "2019-03-20 05:03:56"
  ["add_date"]=>
  string(19) "2019-03-20 05:03:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1980"
  ["article_id"]=>
  string(4) "1980"
  [1]=>
  string(38) "Oral ulceration: causes and management"
  ["article_title"]=>
  string(38) "Oral ulceration: causes and management"
  [2]=>
  string(150) "Patients often present in community pharmacy with mouth ulcers. This article describes the aetiology, presentation and treatment options for six types"
  ["short_description"]=>
  string(150) "Patients often present in community pharmacy with mouth ulcers. This article describes the aetiology, presentation and treatment options for six types"
  [3]=>
  string(151) "Patients often present in community pharmacy with mouth ulcers. This article describes the aetiology, presentation and treatment options for six types."
  ["description"]=>
  string(151) "Patients often present in community pharmacy with mouth ulcers. This article describes the aetiology, presentation and treatment options for six types."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(119) "https://www.pharmaceutical-journal.com/learning/learning-article/oral-ulceration-causes-and-management/20205786.article"
  ["blog_url"]=>
  string(119) "https://www.pharmaceutical-journal.com/learning/learning-article/oral-ulceration-causes-and-management/20205786.article"
  [15]=>
  string(19) "2019-03-19 22:20:00"
  ["add_date"]=>
  string(19) "2019-03-19 22:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:55"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:55"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2013"
  ["article_id"]=>
  string(4) "2013"
  [1]=>
  string(134) "Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder"
  ["article_title"]=>
  string(134) "Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder"
  [2]=>
  string(150) "IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar. 19, 2019-- Urovant Sciences (Nasdaq: UROV),a clinical-stage biopharmaceutical company f"
  ["short_description"]=>
  string(150) "IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar. 19, 2019-- Urovant Sciences (Nasdaq: UROV),a clinical-stage biopharmaceutical company f"
  [3]=>
  string(245) "IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar. 19, 2019-- Urovant Sciences (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today..."
  ["description"]=>
  string(245) "IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar. 19, 2019-- Urovant Sciences (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/urovant-sciences-announces-positive-topline-results-pivotal-phase-3-empowur-study-vibegron-patients-18095.html?utm_source=ddc&utm_medium=rss&utm_campaign=Urovant+Sciences+Announces+Positive+Topline+Results+from+Pivotal+Phase+3+EMPOWUR+Study+of+Vibegron+in+Patien"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/urovant-sciences-announces-positive-topline-results-pivotal-phase-3-empowur-study-vibegron-patients-18095.html?utm_source=ddc&utm_medium=rss&utm_campaign=Urovant+Sciences+Announces+Positive+Topline+Results+from+Pivotal+Phase+3+EMPOWUR+Study+of+Vibegron+in+Patien"
  [15]=>
  string(19) "2019-03-19 11:03:36"
  ["add_date"]=>
  string(19) "2019-03-19 11:03:36"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1916"
  ["article_id"]=>
  string(4) "1916"
  [1]=>
  string(278) "Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)"
  ["article_title"]=>
  string(278) "Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 5"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 5"
  [3]=>
  string(251) "Audience: Consumer, Health Professional, Pharmacy Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc...."
  ["description"]=>
  string(251) "Audience: Consumer, Health Professional, Pharmacy Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc...."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-usp-25mg-14256.html?utm_source=ddc&utm_medium=rss&utm_campaign=Legacy+Pharmaceutical+Packaging%2C+LLC+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+Tablets%2C+USP%2C+25mg%2C"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-usp-25mg-14256.html?utm_source=ddc&utm_medium=rss&utm_campaign=Legacy+Pharmaceutical+Packaging%2C+LLC+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+Tablets%2C+USP%2C+25mg%2C"
  [15]=>
  string(19) "2019-03-19 08:00:00"
  ["add_date"]=>
  string(19) "2019-03-19 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2133"
  ["article_id"]=>
  string(4) "2133"
  [1]=>
  string(59) "The Role of the Student Engineer in Medicine and Innovation"
  ["article_title"]=>
  string(59) "The Role of the Student Engineer in Medicine and Innovation"
  [2]=>
  string(150) "The last 50 years have seen many great technical advances in medical treatments, ranging from drug delivery and imaging to skin grafts and prosthetics"
  ["short_description"]=>
  string(150) "The last 50 years have seen many great technical advances in medical treatments, ranging from drug delivery and imaging to skin grafts and prosthetics"
  [3]=>
  string(376) "The last 50 years have seen many great technical advances in medical treatments, ranging from drug delivery and imaging to skin grafts and prosthetics. These advances—both large and small—have drawn on many fields and have transformed patient care. When examining the current state of clinical technology, the focus is naturally on the technology and its […]"
  ["description"]=>
  string(376) "The last 50 years have seen many great technical advances in medical treatments, ranging from drug delivery and imaging to skin grafts and prosthetics. These advances—both large and small—have drawn on many fields and have transformed patient care. When examining the current state of clinical technology, the focus is naturally on the technology and its […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/uCr0jOXbKKQ/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/uCr0jOXbKKQ/"
  [15]=>
  string(19) "2019-03-19 01:08:49"
  ["add_date"]=>
  string(19) "2019-03-19 01:08:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1847"
  ["article_id"]=>
  string(4) "1847"
  [1]=>
  string(111) "Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019"
  ["article_title"]=>
  string(111) "Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019"
  [2]=>
  string(150) "SMi Group reports: Senior expert from SCHOTT Pharmaceutical Systems is set to present at Pre-Filled Syringes East Coast Conference in just four weeks&"
  ["short_description"]=>
  string(150) "SMi Group reports: Senior expert from SCHOTT Pharmaceutical Systems is set to present at Pre-Filled Syringes East Coast Conference in just four weeks&"
  [3]=>
  string(520) "SMi Group reports: Senior expert from SCHOTT Pharmaceutical Systems is set to present at Pre-Filled Syringes East Coast Conference in just four weeks’ time in Boston, USA. The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA in April 8th – 9th 2019. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(520) "SMi Group reports: Senior expert from SCHOTT Pharmaceutical Systems is set to present at Pre-Filled Syringes East Coast Conference in just four weeks’ time in Boston, USA. The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA in April 8th – 9th 2019. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(109) "http://www.realwire.com/releases/Exclusive-speaker-interview-released-for-Pre-Filled-Syringes-East-Coast-2019"
  ["blog_url"]=>
  string(109) "http://www.realwire.com/releases/Exclusive-speaker-interview-released-for-Pre-Filled-Syringes-East-Coast-2019"
  [15]=>
  string(19) "2019-03-15 22:00:00"
  ["add_date"]=>
  string(19) "2019-03-15 22:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-22 13:42:54"
  ["create_at"]=>
  string(19) "2019-04-22 13:42:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5272"
  ["article_id"]=>
  string(4) "5272"
  [1]=>
  string(42) "Pharmaceutical Regulatory Affairs in China"
  ["article_title"]=>
  string(42) "Pharmaceutical Regulatory Affairs in China"
  [2]=>
  string(111) "A detailed overview of the key areas of pharmaceutical regulatory affairs in China, Hong Kong Macau and Taiwan."
  ["short_description"]=>
  string(111) "A detailed overview of the key areas of pharmaceutical regulatory affairs in China, Hong Kong Macau and Taiwan."
  [3]=>
  string(111) "A detailed overview of the key areas of pharmaceutical regulatory affairs in China, Hong Kong Macau and Taiwan."
  ["description"]=>
  string(111) "A detailed overview of the key areas of pharmaceutical regulatory affairs in China, Hong Kong Macau and Taiwan."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(74) "https://www.pharmiweb.com/event/pharmaceutical-regulatory-affairs-in-china"
  ["blog_url"]=>
  string(74) "https://www.pharmiweb.com/event/pharmaceutical-regulatory-affairs-in-china"
  [15]=>
  string(19) "2019-03-15 18:50:01"
  ["add_date"]=>
  string(19) "2019-03-15 18:50:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:27"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5270"
  ["article_id"]=>
  string(4) "5270"
  [1]=>
  string(65) "Medical Device Software: Complying with the MDR & FDA Regulations"
  ["article_title"]=>
  string(65) "Medical Device Software: Complying with the MDR & FDA Regulations"
  [2]=>
  string(135) "An Introduction to Medical Device Software: Regulations & Requirements to include EU & FDA Guidance and Risk Management"
  ["short_description"]=>
  string(135) "An Introduction to Medical Device Software: Regulations & Requirements to include EU & FDA Guidance and Risk Management"
  [3]=>
  string(135) "An Introduction to Medical Device Software: Regulations & Requirements to include EU & FDA Guidance and Risk Management"
  ["description"]=>
  string(135) "An Introduction to Medical Device Software: Regulations & Requirements to include EU & FDA Guidance and Risk Management"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(96) "https://www.pharmiweb.com/event/medical-device-software-complying-with-the-mdr-fda-regulations-1"
  ["blog_url"]=>
  string(96) "https://www.pharmiweb.com/event/medical-device-software-complying-with-the-mdr-fda-regulations-1"
  [15]=>
  string(19) "2019-03-15 18:47:58"
  ["add_date"]=>
  string(19) "2019-03-15 18:47:58"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:27"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}